A research team at Guangzhou Medical University has developed NeoPred, a novel AI platform combining dual-phase CT imaging and clinical data to predict pathological responses of non-small cell lung cancer (NSCLC) to neoadjuvant chemo-immunotherapy preoperatively. The model integrates imaging changes before and after therapy with clinical parameters using 3D convolutional neural networks, enabling personalized treatment planning. This advancement improves dynamic assessment capabilities and may optimize outcomes for NSCLC patients undergoing multimodal therapies.